MSLN抗体—艾普蒂

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Western blot analysis using MSLN mouse mAb against CHO3D10 (1), SK-MES-1 (2), and HL-60 (3) cell lysate.    

  
  

•  

   

     Flow cytometric analysis of Hela cells using MSLN mouse mAb (green) and negative control (red).    

  
  

Mesothelin (MSLN) is a cell surface glycoprotein anchored by glycosylphosphatidylinositol (GPI), primarily expressed in mesothelial cells lining pleura, pericardium, and peritoneum. Its physiological role remains unclear, but it is implicated in cell adhesion and signaling. MSLN gained attention as a therapeutic target due to its overexpression in multiple aggressive cancers, including mesothelioma, pancreatic, ovarian, and lung adenocarcinomas, while showing limited expression in normal tissues. This tumor-restricted expression makes it an attractive candidate for antibody-based therapies.

MSLN-targeting antibodies are designed to exploit this differential expression. Formats include naked monoclonal antibodies (e.g., amatuximab), antibody-drug conjugates (ADCs), and chimeric antigen receptor (CAR) T-cell therapies. These antibodies bind MSLN to either directly inhibit tumor growth, deliver cytotoxic payloads, or redirect immune cells against cancer. Challenges include managing on-target/off-tumor toxicity due to low MSLN levels in some normal tissues (e.g., fallopian tube epithelium) and antigen heterogeneity in tumors.

Current research focuses on improving antibody specificity, combining MSLN-targeting agents with chemotherapy or immunotherapy, and developing next-generation engineered antibodies with enhanced tumor penetration and reduced immunogenicity. Several candidates, such as anetumab ravtansine (ADC) and listeria-based vaccines, are in clinical trials, showing preliminary antitumor activity with manageable safety profiles.